Trial Profile
A Randomized Controlled Trial of Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Extended-Spectrum ß-lactamase-producing Escherichia Coli
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ertapenem (Primary) ; Sitafloxacin (Primary)
- Indications Pyelonephritis
- Focus Therapeutic Use
- Acronyms SETAP
- 04 Sep 2015 New trial record